Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD), dubbed HG202, developed using machine learning and AI.
The company used its HG-PRECISE platform (HuidaGene – Platform for Rational Engineering of...
